Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novartis

Stocks To Watch: Novartis ADR Sees RS Rating Jump To 83

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance.

Investors Business Daily

Novartis ADR Receives Composite Rating Upgrade

On Wednesday, Novartis ADR got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.

Investors Business Daily

Behind $2 million per dose gene therapy

How did a drug rooted in government seed money and spurred by grassroots fundraising end up with such a price tag?

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Aliens, sloths and silliness: Super Bowl ads offer laughs, celebs and surprises to win over viewers

Eugene Levy’s trademark eyebrows fly off for Little Caesars

The Independent UK

Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition

Novartis stock closed flat Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.

Investors Business Daily

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

MarketBeat

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Investors Business Daily

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Benzinga

From biopharma to real estate to shipping, top CEOs insist AI is worth the hype

Stop being afraid of newfangled technology, and start letting your kids use it to help them with their homework, said panelists at Fortune Global Forum.

Fortune

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations.

Investors Business Daily

'Pure-play' Novartis Raises 2024 Financial Targets

A year after spinning off its generics business to become a "pure-player" developer of innovative medicines, Novartis registered a 15 percent increase in its core net profit to $4.1 billion during the July-September period, from the same quarter last year.

International Business Times

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

Monte Rosa Therapeutics shares nearly doubled Monday on a deal with Novartis to develop treatments for immune system conditions.

Investors Business Daily

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Chart of the Day: Novartis - Take Another Look

The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Investors Business Daily

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

International Business Times

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

Investors Business Daily

Novartis Dives After Handing Amgen, Bristol — And Their Rivals — A Key Victory

Novartis stock tumbled Thursday after the firm dropped out of a key cancer treatment race vs. big players Amgen and Bristol Myers Squibb.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novartis Stock Generating Improved Relative Strength

Novartis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

Investors Business Daily

Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?

Investors Business Daily

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Investors Business Daily

How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint

Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.

Investors Business Daily

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.

Barchart

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

156 stories

Novartis

131 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.